RxDoctor Payments Data

Andrew Vitale, MD

Urology · Oklahoma City, OKNPI 1114311271

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (45.2%), food and beverage and education — rather than concentrated in one kind of arrangement. 34 manufacturers reported payments, led by Intuitive Surgical at 40.9% of the total.

$8,973in general payments, 2019–2025

Across 111 payments — averaging $80.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$4K
  • Boston Scientific$2K
  • Kerecis Limited$2K
  • Teleflex LLC$282
  • Procept Biorobotics Corporation$195
  • Sumitomo Pharma America, Inc.$143
  • plus $1K from 28 others

What the payments were for

  • Travel & lodging$4,06045%
  • Food & beverage$3,39138%
  • Education$1,50017%
  • Gifts$230%

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,973 in reported general payments places this provider in the 75th percentile of 145 urology providers in Oklahoma.

See all urology providers in Oklahoma

Medicare billing

Part B allowed, 2024
$150,830
Medicare patients
338
Services billed
4,463

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron95$62,613
GemtesaVibegron25$17,099
Tamsulosin Hcl239$3,402
Finasteride164$1,986
Potassium Citrate ErPotassium Citrate20$1,628
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst44$849
Oxybutynin Chloride ErOxybutynin Chloride81$646
Trospium Chloride17$603
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip19$343
Alfuzosin Hcl ErAlfuzosin Hcl20$302
Levofloxacin85$260
Doxycycline Hyclate30$249
Cefdinir14$235
Cephalexin33$220
Solifenacin Succinate11$153

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$88$62,61395 claims
Sumitomo Pharma America, Inc.Gemtesa$143$17,09925 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 145 urology providers in Oklahoma.

Other urology in Oklahoma City

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →